The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2018 | Predictors of outcome for follicular lymphoma
The Genomics England program could play a key role in personalizing the treatment of patients with follicular lymphoma, through helping identify predictors of treatment outcome. Speaking at British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK, Anna Schuh, MD, PhD, MRCP, FRCPath, from Oxford University Hospitals, Oxford, UK, shares her research showing that the combination of clinical parameters and genomic markers offers a more accurate predictive value compared with each in isolation. Dr Schuh also discusses the current issue of sourcing high quality germ line specimens, which are required to identify mutations predictive of outcomes.
